During a long-term treatment period of up to four years, persistent effects and further increased clinical and immunological benefits are achieved. This has been shown for grass, cat and dog, and house dust mites [
28,
82,
83]. In a study using two consecutive pre-seasonal short-courses of a grass pollen allergoid, using a combined symptom medication score it was clear that although the treatment was clinically effective in the first season, its clinical efficacy was even better in the second seasonal [
51]. An open continuation of this study including a third pre-seasonal treatment period confirmed the increased efficacy potential which prolonged immunotherapy treatment provides [
54]. When continuing the treatment for more than 12 months it is possible to introduce non-specific efficacy parameters, seen as a decrease in the patient's non-specific bronchial hyper responsiveness as an indicator of inflammation. This was shown in patients suffering from house dust mite related allergic asthma, who increased their tolerance to bronchial challenge with house dust mite allergen after six months, but it was only after 18 months of SIT that a persistent reduced bronchial inflammation and hyperresponsiveness measured by bronchial challenge with metacholine was found [
84]. It has also been observed that two years of immunotherapy prevented the seasonal onset of bronchial hyperresponsiveness in grass pollen allergic patients with rhinitis and asthma [
29]. According to a meta-analysis on asthma, SCIT significantly reduced allergen specific bronchial hyperresponsiveness, which was evaluated in the majority of the studies done after one year of treatment [
61]. The finding that SIT is able to improve specific bronchial hyperreactivity is important from a clinical point of view. Indeed, patients with brittle allergic asthma are at risk of sudden deterioration when exposed to increased levels of an aeroallergen to which they are sensitive, as in the case of mould allergic patients. Currently, the measurement of BHR is the only accurate method of assessing such a risk and any intervention which reduces the risk of an acute episode of asthma under these circumstances would be clinically useful. Moreover, a high percentage of children and adults also develop a late asthmatic response after an allergen specific bronchial challenge [
85], the presence of which is considered an experimental model close to resembling chronic bronchial allergic inflammation. Subcutaneous SIT is able to decrease not only early, but also late asthmatic responses following allergen specific bronchial challenge, thus confirming the anti-inflammatory effect of the treatment in the lung [
53].
A Th2/Th1 response towards normal balance is usually associated with a positive clinical effect of immunotherapy. In grass pollen allergic patients undergoing injection immunotherapy it has been shown that a significant change towards a Th1 response measured by the level of interferon-gamma in peripheral blood was achieved after a 12-month treatment period, but not after just three months treatment -despite a well-documented symptomatic effect being found after three months [
30]. Administering a short four-week therapy with a grass allergen extract together with an MPL adjuvant showed that specific IgG and IgG4 levels increased only slightly in year one of SIT, but which became highly significant in year two [
86]. A progressive immunological change as indicated by the significant induction of non-IgE competitive antibodies was also observed in year two of treatment with a sublingual tablet for grass pollen allergy whose clinical efficacy comparable to the benefits of year one [
87]. In a three-year long-term SIT study in grass allergic patients with both rhinoconjunctivitis and asthma the asthma symptoms had completely cleared after 3 years with a general progression in clinical effect over the years. Symptoms and the need for medication was generally reduced from the beginning although nasal symptoms were not reduced during the first season - again indicating that continuing the treatment will increase the benefits [
88].